Genome-wide methylation is reduced in IDH1/2mt AML cells after patients have been treated with mtIDH1/2 inhibitors, but a gene expression profile associated with AML stemness persisted, suggesting that a complete reversal of the mtIDH1/2-induced DNA hypermethylation is not necessary for a clinical response.54 In addition to these data, a longitudinal study of patients with IDH1mt cholangiocarcinoma that was treated with ivosidenib was performed. This evidence concerns the gene IDH1 and cholangiocarcinoma.